Brief: Matinas Biopharma Provides Update To Mat2203 Regulatory And Development Pathway after Feedback From FDA
21/12/2023 12:40
Dec 21 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA PROVIDES UPDATE TO MAT2203 REGULATORY
AND
DEVELOPMENT PATHWAY FOLLOWING FEEDBACK FROM FDA
* MATINAS-PLANNING MEETING EARLY IN Q1 2024 TO DISCUSS &
FINALIZE
PHASE 3 PROTOCOL & POSITION MAT2203 TO COMMENCE PHASE 3 AS SOON
AS POSSIBLE THEREAFTER
Source text for Eikon: ID:nGNX2TB640
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors